Mural Oncology plc (MURA) saw a significant rise in its stock price on January 10, 2025, closing at $3.89, up 6.58% from the previous day's close of $3.65. The stock opened at $3.90 and reached a high of $4.00, with a low of $3.64, driven by substantial trading volume of 577,694 shares, which is 343.98% of its average daily volume. This surge in activity and price was fueled by the company's announcement of
Mural Oncology plc (MURA) is experiencing a boost in its stock price following the company's announcement of significant advancements in its drug development pipeline. The company has reported progress in the trials of its investigational therapy, nemvaleukin, which is being tested for ovarian cancer and melanoma. Additionally, Mural Oncology has extended its cash runway into the first quarter of 2026, than